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Rheumatology Division, IOT, Florence, ItalySINCE Ho#man synthesized aspirin (ASA), more
than 100 years ago, there is a general agreement
that nonsteroidal antiinflammatory drugs
(NSAIDs) provide symptomatic relief for millions
of people with osteoarthritis (OA). The role of
NSAIDs became confused with the discovery that
some R-enantiomers of the profenic group of
NSAIDs were as e#ective as S-series enantiomers
in relieving pain in OA. This was despite the fact
that the R-enantiomeres were several hundred
fold less active in inhibiting prostaglandin (PG)
synthesis and ine#ective in animal models of
inflammation.
The value of NSAIDs in OA became further
confused with the frequency of adverse reactions
(particularly in the elderly) and reports of rapid
destructive arthropathy in patients taking high
doses of indomethacin. Consequently, Brandt
(1993) published a sharp review with an intriguing
title: ‘Should OA be treated with NSAID?’
We do not yet fully understand the etiopatho-
genesis of OA and the mechanism of NSAIDs
activity on the intrinsic and migrating cells of the
joint. What is known is controversial and filled
with personal opinions. Animal models have been
of some help in defining these processes.
If we are to assume that NSAIDs are e#ective in
providing symptomatic relief and that NSAIDs
have analgesic as well as anti-inflammatory
properties, we can pose the following questions: (1)
what is the evidence that OA is an inflammatory
joint disease and (2) what is the evidence that the
joint pain in OA is due to synovitis?Inflammation
We know the histology of early and advanced
OA and that the correlation between histologic
evidence of synovitis and cartilage damage is
inconsistent. Evidence exists that macrophage351or autocrine chondrocyte produced cytokines,
like interleukin (IL)-1 and tumor necrosis fac-
tor (TNF)-Æ, can accelerate the breakdown of
articular cartilage. Through the interleukin 1
receptor (IL-1R) and the tumor necrosis factor
alpha receptor (TNF-ÆR), cytokines precipitate the
inducible enzymes nitric oxide (NOS)-2 and
cyclooxygenase (COX)-2. Through these mecha-
nisms, NSAIDs can be useful by reducing cytokine
production, toxic oxygen free radicals, noxious
prostaglandins, leukotriene synthesis, etc.
However, the biochemical and metabolic
changes of OA in the articular cartilage of
anterior cruciate deficient (ACLT) canines appear
independent of the presence of synovitis. Treat-
ment with prednisone, low enough to not inhibit
PG synthesis by chondrocytes but high enough to
inhibit IL-1 production, had no e#ects on the
development of OA in the model. Moreover the
indiscriminate blockage of PG production reduce
the presence of PGE-2 which normally has a stimu-
lating activity, via adenyl cyclase, on uridine
diphosphate-glucose deydrogenase and glutamine-
fructose-6-phosphate aminotransferase—enzymes
employed in the synthesis of hexuronic acid and
chondroitin sulfate.
PGE-2 also has a feedback e#ect in reducing the
production of IL-1 by macrophages and in IL-1R
expression on chondrocytes. PG analogues admin-
istered with NSAIDs have been shown to diminish
the deleterious e#ects of NSAIDs on cartilage.Is there evidence for a direct effect of
NSAIDs on articular cartilage metabolism?
From observations in animal models of OA,
there is a di#erent response of cartilage to di#er-
ent NSAIDs: (1) OA was markedly accelerated in
C57Black mice, who develop a spontaneous OA;
(2) dogs fed with ASA had significantly lower
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matrix; (3) water content was increased by
naproxen in ACLT canines; (4) depletion of matrix
proteoglycans with increased degeneration of
cartilage chondrocytes from the e#ects of NSAIDs.
However, some NSAIDs show a favorable e#ect
on OA articular cartilage – although there are
di#ering results in di#erent models: (1) in a study
of proteoglycan metabolism of cartilage explants,
Palmosky et al. showed di#erent e#ects of di#er-
ent NSAIDs; (2) pirprofen significantly reduced
cartilage breakdown severity in rabbits; (3) tiapro-
fenic acid reduced the size of ulcers on femoral
condyles and tibia plateaus and produced less
marked histological changes in ACLT dogs; (4)
tiaprofenic acid showed a chondroprotective
action in the ACLT canine model; and (5) tiapro-
fenic acid in a prophylactic treatment, prevented
OA progression in the ACLT canine model.
There is less controversy on the e#ects of
NSAIDs on catabolism: (1) NSAIDs are credited on
having some favorable e#ects on the cartilage
metabolism in controlling degradation of cartilage
matrix; (2) in relation to inhibition of proteinases,
tenoxicam and indomethacin have opposite e#ect
on the activation of stromelisin; (3) etodolac
administered as ‘prophylactic’ in a rabbit exper-
imental OA, partly prevented cartilage disruption;
(4) piroxicam decreased fibrinolytic activity by
increasing plasminogen activator inhibitor (PAI)
activity and decreasing urokinase-plasminogen
activator (u-PA) release. this favors the surface
clearance of urokinase-plasminogen activator
receptor (u-PAR) in vitro and in vivo.Plasminogen activator
Our laboratory has been interested in the u-PA
cascade and its relation to articular cartilage
breakdown. Resident articular cells secrete PAs
and PAIs, and express u-PAR on their membrane
[1, 2]. Data indicate that synthesis and release of
u-PA and PAI-1 by both chondrocytes and synovio-
cytes are under the control of a variety of
cytokines and grow-factors found in the diseasedjoints. Secretion of u-PA is followed by autocrine
and paracrine binding to cell surface u-PAR,
which concentrates the u-PA activity at the
cytoplasmic membrane.
Receptor-bound u-PA activates a multi-enzyme
cascade by operating a cleavage on plasminogen,
which is transformed into serine-protease plasmin.
Plasmin degrades directly or indirectly, through
activation of pro-matrix metalloproteinase
(MMP), the greatest part of extracellular matrix
molecules. Data indicate that the activation of
pro-MMPs results from the upstream interaction
of u-PA and u-PAR and the following activation of
proteolytic cascades [3].
Our hypothesis is that upstream inhibition of
u-PAR is mandatory to control all the mechanisms
which involved in cell invasion, matrix degrada-
tion, neo-angiogenesis, and cell growth. These are
strict requirements for resident articular cells that
mediate inflammatory and degenerative joint
pathologies. To demonstrate this we used the anti-
sense oligonucleotide tecnology to control the
expression of u-PAR in synoviocytes and chondro-
cytes: the blockade of u-PAR expression results in
impairment of all the u-PA/uPAR-dependent
events.
As previously published, many NSAIDs can
control and reduce, in di#erent ways and grades,
the u-PA production and u-PAR expression on the
surface of chondrocytes and synoviocytes,
accounting so of a reduced activity on cartilage
breakdown [1, 2].References
1. Fibbi G, Serni U, Matucci A, Mannoni A, Pucci M,
Anichini E, Del Rosso M. Control of the chondro-
cyte fibrinolytic balance by the drug Piroxicam:
relevance to the osteoarthritic process. J
Rheumatol 1994;21:2322–8.
2. Del Rosso M, Fibbi G, Magnelli L, Pucci M, Dini G,
Grappone C, Caldini R, Serni U, Colombo F,
Borella F. Modulation of urokinase receptors on
human synovial cells and OA chondrocytes by
diacetylrhein. Int J Tiss Reac 1987;12:91–100.
3. Vassalli JD, Pepper MS. Membrane proteases in
focus. Nature 1994;370:14–5.
